Business
Arecor Granted Key Canadian Patent
Arecor Granted Key Canadian Patent.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0205S\n Arecor Therapeutics PLC\n 11 November 2021\n \n \n \n \n Arecor Therapeutics plc\n \n \n (\"Arecor\" or the \"Group\")\n \n \n \n \n \n ARECOR GRANTED KEY CANADIAN PATENT FOR PROPRIETARY TECHNOLOGY ENABLING HIGHLY CONCENTRATED BIOTHERAPEUTICS\n \n \n \n \n \n \n Cambridge, UK, \n \n 11 November 2021.\n Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, \n continues to build a strong patent portfolio protecting its\n proprietary \n Arestat™ technology. Arecor is pleased to announce that the Canadian Intellectual Property Office has granted a key patent, CA2861402, with claims protecting a specific part of the technology used in the development of stable, low-viscosity formulations of highly concentrated protein therapeutics, including monoclonal antibodies, fusion proteins and more complex protein constructs. \n \n \n \n \n \n \n Dr Jan Jezek, Chief Scientific Officer at Arecor, commented\n \n : \"The recently granted Canadian patent is an important milestone in our rapidly growing patent portfolio. We have been very successful in patenting unique combinations of excipients that improve considerably critical quality attributes of protein and peptide-based therapeutics, enabling their convenient delivery. This new patent relates specifically to concentrated protein formulations, which is one of the most challenging areas of the biopharmaceutical drug delivery. It strengthens our IP portfolio and our position as a world leader in the formulation of superior biotherapeutics and vaccines.\"\n \n \n \n \n \n The Group's Arestat™ technology enables superior product profiles across a broad range of therapies, including various types of biopharmaceuticals, specialty hospital products as well as vaccine compositions with improved stability. Arecor partners \n with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products under a technology licensing model, as well as \n developing an internal portfolio of proprietary products in diabetes and other indications.\n \n \n \n \n \n A combination of high therapeutic dose and the highly desirable low injection volume often leads to a need for very highly concentrated formulations of protein therapeu...